| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against Pseudomonas infections. |
| Indication |
For the treatment of bacterial infections caused by susceptible microorganisms. |
| Pharmacology |
Cefoperazone is a third generation cephalosporin antibiotic. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis |
| Toxicity |
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting. |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
No significant quanitity of metabolites have been identified in urine. |
| Half Life |
The mean serum half-life is approximately 2.0 hours, independent of the route of administration. |
| Protein Binding |
The degree of reversible protein binding varies with the serum concentration from 93% at 25 mcg/mL to 90% at 250 mcg/mL and 82% at 500 mcg/mL. Cefotetan is 88% plasma protein bound. |
| Elimination |
Cefoperazone is excreted mainly in the bile. |
| References |
| • |
Jones RN, Barry AL: Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S108-26.
[Pubmed]
|
|
| External Links |
|